As Virtual Care Surges, Pharma Organizations Need to Reimagine Patient and Provider Engagement Strategies

We’ve all seen the headlines about the tsunami of growth expected to hit telehealth and virtual delivery of care. Recent events related to COVID-19 have certainly been one key market driver, however, explorations into the use of telehealth and telemedicine have been steadily increasing for more than two decades.

This presents a real opportunity for life sciences and pharmaceutical organizations to meet patients and the members of their care teams where they are–– whether that’s virtual or in person –– and to support the creation of more connected experiences across the care continuum.

To achieve this, many organizations will have to rethink their long-term digital strategy and whether it supports connected experiences –– and more importantly, if it’s sustainable.